𝔖 Bobbio Scriptorium
✦   LIBER   ✦

De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients

✍ Scribed by Li-Chun Wang; En-Qiang Chen; Jing Cao; Li Liu; Li Zheng; Da-Jiang Li; Lu Xu; Xue-Zhong Lei; Cong liu; Hong Tang

Book ID
107593934
Publisher
Springer-Verlag
Year
2011
Tongue
English
Weight
243 KB
Volume
5
Category
Article
ISSN
1936-0533

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Entecavir treatment for chronic hepatiti
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
✍ Roeland Zoutendijk; Jurriën G. P. Reijnders; Ashley Brown; Fabien Zoulim; David 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 1 views

Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients. The aim of this study was to investigate the long term efficacy and safety of ETV in NA-naïve CHB patients, particularly in those with detectable hepatitis B virus (HBV

Corrections: Entecavir treatment for chr
Corrections: Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 1 views

In the August 2011 issue of HEPATOLOGY, in the article entitled ''Carcinogen-induced hepatic tumors in KLF6þ/À mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation'' (volume 54, pages 522-531), Dr.